Leukemia Clinical Trials in San Francisco

Showing 861-880 of 893 trials

Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors

NCT00112619

RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I trial is studying the side effects, best way to give, and best dose of topotecan when given by intraventricular infusion in treating young patients with neoplastic meningitis due to leukemia, lymphoma, or solid tumors.

Brain and Central Nervous System TumorsCarcinoma of Unknown PrimaryLeukemia+2 more

Pediatric Brain Tumor Consortium19 participantsStarted Aug 2005

San Francisco, California, United States • Washington D.C., District of Columbia, United States • Chicago, Illinois, United States +8 more locations

UNKNOWNPhase 3< 1 mile

Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study

NCT00715637

Amonafide is a DNA intercalating agent and inhibitor of topoisomerase II that has been extensively studied in patients with malignant solid tumors. Amonafide has also been studied in patients with AML. The purpose of this study is to assess the relative efficacy and safety of amonafide in combination with cytarabine compared to daunorubicin with cytarabine in subjects with documented secondary AML.

Secondary Acute Myeloid Leukemia (Secondary AML, sAML)

Antisoma Research420 participantsStarted Jun 2007

Los Angelas, California, United States • Los Angeles, California, United States • San Francisco, California, United States +155 more locations

Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors

Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study

Leukemia Trials in Other Cities

Bortezomib (Velcade) + Pemetrexed (Alimta) in Advanced NSCLC

Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT

STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.

Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma

A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC

Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia

The LIFE Study: Lifestyle Interventions and Independence for Elders, Pilot

T-cell Minimal Residual Disease (MRD) Evaluation Using Flow Cytometric Analysis

Bone Marrow Transplantation in Treating Patients With Leukemia, Myelodysplasia, or Lymphoblastic Lymphoma

CPG 7909 Injection in Non-Small Cell Lung Cancer

Picoplatin as Second-Line Therapy for Patients With Small Cell Lung Cancer

Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia

A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer

Oral NRX 194204 Study in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML)

Study of AT-101 in Combination With Topotecan in Relapsed/Refractory Small Cell Lung Cancer

Analgesic Efficacy And Safety of Valdecoxib For Treatment Of Post-Surgical Pain From Bunionectomy Surgery

Other Conditions in San Francisco